Cross-vaccinationดาวน์โหลด SLOTXOagainst COVID-19 produces high levels of antibodies equal to or higher than the original brand as the trigger. Based on the preliminary data of a long-awaited trial supported by the US government.
The results of the study, funded by the National Institutes of Health (NIH), were long-awaited in the United States. because it is a research study that considers the possibility of "cross the line vaccination" or use another vaccine as a booster which is not currently approved in the United States.
It was the first large-scale research study in the United States. that compares the effectiveness of different vaccines be a stimulant More than 450 volunteers were involved and the immunizations were measured by Moderna, Inc., Pfizer-Biontech or johnson johnson for people who received different brands of vaccination needles.
Overall, the study found that the effect of "Cross vaccination" produces equal or higher negative or negative antibody levels. compared to booster injections with the same vaccine Researchers posted their results prior to publication on medRxiv.org, while the incidence of post-vaccination adverse reactions was similar.
r0;This data indicates that if a vaccine is approved or approved as a booster, It can trigger an immune response. regardless of the initial COVID-19 vaccination regimen,r1; the researchers conclude.
The results of this ongoing experiment It has not been reviewed and published in a medical journal. However, more details about the study are expected to be published at the US Food and Drug Administration (FDA) advisory panel meeting on Friday (15 Oct. Their findings are scheduled to be presented first at the meeting.
Cross-border vaccination has become an increasingly important issue. Many other countries besides the United States have already adopted this method. In an effort to increase the effectiveness of the vaccine or avoid the rare side effects associated with certain brands of vaccines.
Portal
